Experienced in Cell and Gene Therapy:
Like Amplify Bio, Noble specializes in preclinical studies for advanced therapies. We offer GLP and non-GLP toxicology, PK/PD studies, biodistribution, and assay development tailored to complex modalities.
Fast, Flexible, and Responsive:
We know time is critical. Our team can quickly assess your study needs, map next steps, and get your program back on track—often with faster turnaround than larger CROs. We understand the urgency of your projects and offer swift integration into our systems.
Full-Service Support Under One Roof:
From study design optimization to execution and reporting, we provide a seamless experience with dedicated scientific leads and transparent communication. With state-of-the-art facilities, we are equipped to handle complex studies with precision and compliance.
Proven Track Record: Trusted by numerous biotech companies for our reliability and expertise.
Yes. Noble Life Sciences has deep experience in preclinical research for cell and gene therapies, including GLP and non-GLP studies, pharmacokinetics, toxicology, and assay development.
We’re currently onboarding clients from Amplify Bio and are ready to support more teams affected by the shutdown. Let us know how we can help. Contact us today.
Hear what our clients have to say about working with us.
“Noble has been instrumental in enabling the accelerated testing of Jaguar’s preclinical gene therapy program. We are impressed by Noble’s experience and unparalleled support. As a leader in drug, device, and vaccine development, Noble appreciates the significance of Jaguar’s mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases.”
“Noble has been a strong partner for us, helping to accelerate testing of our synthetic biologics. Our Amicidins are new and innovative, requiring special attention to local application and performance in models. Noble has been flexible and agile in meeting our needs with high-quality work. We are pleased with the part Noble has played in advancing our programs, as we look to prevent and treat life-threatening infections in surgery and trauma.”
– Director, Preclinical Development
– CEO, Britecyte, Inc.
– Co-Founder, DEKA BioSciences
“We needed a local CRO that is flexible and fast-paced to support our AAV gene therapy research and preclinical programs. Luckily, we found Noble who exceeded our expectations. Our teams work seamlessly as if they are an extension of our lab and provided necessary resources to advance our research in the most cost-effective way.”
– VP, Target Discovery & Early Portfolio
View whitepapers, webinars, and resources from Noble Life Sciences experts to advance your programs.
